“I am seeing this process rapidly expand, particularly with the use of the single-port robot, which offers additional benefits to things like pain control and helps to further expedite early discharge,” Andrew Wood, MD.
In this video, Andrew Wood, MD, discusses the rollout of a same-day discharge protocol after robot-assisted partial nephrectomy. Wood was first author of the recent Journal of Endourology study, “Same-Day Discharge After Robot-Assisted Partial Nephrectomy: Is It Worth It?” Wood is a urologic oncology fellow at Glickman Urological & Kidney Institute at Cleveland Clinic in Cleveland, Ohio.
At Maimonides Medical Center, the practice has rapidly expanded into essentially all providers providing partial nephrectomy and all affiliated individuals, including the postanesthesia care unit [PACU], the nursing staff, and the residents, continue to make improvements on the process. [This includes] things like the PACU nursing team understanding the pace at which patients need to progress to the milestones before they can be discharged and residents and physicians performing early postoperative checks to allow for patients to make their way through the postoperative protocol and be ready for discharge in an expeditious manner. And then additionally, as a fellow at Cleveland Clinic, I am seeing this process rapidly expand, particularly with the use of the single-port robot, which offers additional benefits to things like pain control and helps to further expedite early discharge.
This transcript was edited for clarity.
FDA expert reviews data supporting belzutifan approval for VHL-associated kidney cancer
November 16th 2023Data from the phase 2 LITESPARK-004 trial led to the FDA approval of belzutifan for patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma and other diseases.
CAR T-cell therapy explored as potential option for advanced renal cell carcinoma
November 13th 2023Researchers are exploring the potential of CAR T-cell therapy in patients with renal cell carcinoma who have disease progression following treatment with checkpoint inhibitors and VEGF inhibitors.
Adjuvant pembrolizumab improves overall survival in certain patients with renal cell carcinoma
November 1st 2023Adjuvant pembrolizumab improved overall survival compared with placebo in patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.